Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in Patients With Advanced Malignant Solid Tumors
NCT05171790Phase 1Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Dec 2021
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QL1706 in solid tumor (advanced stage), sponsored by Qilu Pharmaceutical. Primary endpoint: Objective Response Rate up to 24 weeks. Status: unknown.
02
Drugs
QL1706
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05171790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05171790.